haematologica the hematology journal

author contribution form

| Title | A Phase 2 Multicenter Rabbit Anti-Thymocyte Globulin Trial in Patients with Myelodysplastic Syndromes Identifying a Novel Model for Response Prediction |
|--------------|---|
| First author | Rami S. Komrokji |

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html):

"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

Name:

author(s) responsible for the integrity of the work as a whole

...P.K.Epling-Burnette.....

| Institute: | H. Lee Moffitt Cancer Center |
|------------|------------------------------|
| e-mail: | Pearlie.Burnette@moffitt.org |
| Name: | Rami S. Komrokji |
| Institute: | H. Lee Moffitt Cancer Center |
| e-mail: | Rami.Komrokii@moffitt.org |

Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

RSK conducted the clinical trial and analyzed response data; AWM performed statistical analyses, created figure, collected and analyzed survival data, and assisted with writing the manuscript; DTC is the study statistician; MAS conducted the clinical trial; RP conducted the clinical trial; WJF is a study statistician; CS analyzed biomarker; JPP is the clinical coordinator; JPM conducted the clinical trial; AFL is senior author and PI of the clinical trial. JPM, MAS, RLP, and AFL are members of the Bone Marrow Failure Rare Diseases Clinical Research Network (BMF-RDCRN) who consented patients, obtained samples, and recorded clinical data. PKE-B obtained funding for the project, analyzed data, participated in study design, and wrote the manuscript.